| Drug General Information |
| Drug ID |
D05WSY
|
| Former ID |
DNC003714
|
| Drug Name |
ILOMASTAT
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Preclinical |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H28N4O4
|
| InChI |
InChI=1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1
|
| InChIKey |
NITYDPDXAAFEIT-DYVFJYSZSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
829892, 10243138, 11120050, 11120538, 11121026, 11121715, 11122195, 11147133, 11362833, 11365395, 11367957, 11370897, 11370898, 11373558, 11376119, 12014779, 14878422, 14902905, 17397881, 24902217, 26756835, 26758815, 29310648, 46484604, 46506673, 47364924, 47588747, 48034840, 48258955, 48427395, 50070501, 50071141, 50111444, 50111445, 53790355, 57344178, 79412811, 81060888, 81062449, 81062451, 92310066, 99029951, 99300978, 99302498, 103185416, 103957874, 104377641, 121379601, 124892442, 134340919
|
| Target and Pathway |
| Target(s) |
Interstitial collagenase |
Target Info |
Inhibitor |
[3]
|
|---|
| Matrixmetalloproteinase |
Target Info |
Inhibitor |
[4]
|
| Matrix metalloproteinase-14 |
Target Info |
Inhibitor |
[3]
|
| Neutrophil collagenase |
Target Info |
Inhibitor |
[5]
|
| 72 kDa type IV collagenase |
Target Info |
Inhibitor |
[3]
|
| Stromelysin-1 |
Target Info |
Inhibitor |
[3]
|
| MMP-9 |
Target Info |
Inhibitor |
[3]
|
| MMP-12 |
Target Info |
Inhibitor |
[4]
|
| Collagenase 3 |
Target Info |
Inhibitor |
[6]
|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
Pathways in cancer
|
|
Bladder cancer
|
|
Rheumatoid arthritishsa04668:TNF signaling pathway
|
|
GnRH signaling pathwayhsa04670:Leukocyte transendothelial migration
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Proteoglycans in cancer
|
|
Bladder cancerhsa04668:TNF signaling pathway
|
|
Transcriptional misregulation in cancer
|
|
Leukocyte transendothelial migration
|
|
Hepatitis B
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Wnt Signaling PathwayNetPath_22:Leptin Signaling Pathway
|
|
TCR Signaling Pathway
|
|
ID Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
IL4 Signaling PathwayNetPath_5:ID Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
TNFalpha Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
IL5 Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascadeP00004:Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathwayP00050:Plasminogen activating cascade
|
|
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascade
|
|
Pathway Interaction Database
|
Endothelins
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Glucocorticoid receptor regulatory network
|
|
AP-1 transcription factor network
|
|
Syndecan-1-mediated signaling eventshif2pathway:HIF-2-alpha transcription factor network
|
|
Signaling events mediated by focal adhesion kinaselysophospholipid_pathway:LPA receptor mediated events
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Direct p53 effectors
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Syndecan-2-mediated signaling eventsajdiss_2pathway:Posttranslational regulation of adherens junction stability and dissassembly
|
|
p75(NTR)-mediated signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalinglysophospholipid_pathway:LPA receptor mediated events
|
|
Validated targets of C-MYC transcriptional activation
|
|
CXCR4-mediated signaling events
|
|
Syndecan-4-mediated signaling events
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Syndecan-1-mediated signaling events
|
|
FGF signaling pathwayupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalingupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Basigin interactions
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)R-HSA-1442490:Collagen degradation
|
|
Activation of Matrix MetalloproteinasesR-HSA-1442490:Collagen degradation
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
EGFR Transactivation by GastrinR-HSA-1442490:Collagen degradation
|
|
Degradation of the extracellular matrixR-HSA-1442490:Collagen degradation
|
|
WikiPathways
|
TGF beta Signaling Pathway
|
|
Bladder Cancer
|
|
Activation of Matrix Metalloproteinases
|
|
Degradation of collagen
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Cell surface interactions at the vascular wall
|
|
Matrix MetalloproteinasesWP615:Senescence and Autophagy in Cancer
|
|
AGE/RAGE pathway
|
|
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Matrix MetalloproteinasesWP474:Endochondral Ossification
|
|
IL1 and megakaryotyces in obesity
|
|
Mammary gland development pathway - Involution (Stage 4 of 4)
|
|
Spinal Cord Injury
|
|
TWEAK Signaling Pathway
|
|
Angiogenesis
|
|
Osteopontin Signaling
|
|
Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7409). |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001387) |
|---|
| REF 3 | Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. Epub 2008 Jul 20.Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. |
|---|
| REF 4 | J Med Chem. 2006 Jan 26;49(2):456-8.Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. |
|---|
| REF 5 | Hydroxamate inhibitors of human gelatinase B (92 kDa), Bioorg. Med. Chem. Lett. 5(4):349-352 (1995). |
|---|
| REF 6 | J Biol Chem. 2007 Sep 21;282(38):27781-91. Epub 2007 Jul 10.Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. |
|---|
